Show simple item record

dc.contributor.authorYildirim, Berna Akkus
dc.contributor.authorOnal, Cem
dc.contributor.authorKose, Fatih
dc.contributor.authorOymak, Ezgi
dc.contributor.authorSedef, Ali Murat
dc.contributor.authorBesen, Ali Ayberk
dc.contributor.authorAksoy, Sercan
dc.contributor.authorGuler, Ozan Cem
dc.contributor.authorSumbul, Ahmet Taner
dc.contributor.authorMualloglu, Sadik
dc.contributor.authorMertsoylu, Huseyin
dc.contributor.authorOzyigit, Gokhan
dc.date.accessioned2020-03-05T07:11:53Z
dc.date.available2020-03-05T07:11:53Z
dc.date.issued2019
dc.identifier.issn0179-7158
dc.identifier.urihttp://hdl.handle.net/11727/4590
dc.description.abstractPurpose To evaluate the potential benefit of curative radiotherapy (RT) to the primary tumor in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone. Materials and methods The clinical parameters of 106 mCRPC patients treated with abiraterone were retrospectively evaluated. Patients were either oligometastatic (<= 5 metastases) at diagnosis or became oligometastatic after the systemic treatment was analyzed. Local RT to the primary tumor and pelvic lymphatics was delivered in 44 patients (41%), and 62 patients (59%) did not have RT to the primary tumor. After propensity match analysis, a total of 92 patients were analyzed. Resultsn Median follow-up time was 14.2 months (range: 2.3-54.9 months). Median overall survival (OS) was higher in patients treated with local RT to the primary tumor than in those treated without local RT with borderline significance (24.1 vs. 21.4 months; p=0.08). Local RT to the prostate and pelvic lymphatics significantly diminished the local recurrence rate (16 patients, 31% vs. 2 patients, 5%; p=0.003). In multivariate analysis, the prostate specific antigen (PSA) response >= 50% of the baseline obtained 3 weeks after abiraterone therapy was the only significant prognostic factor for better OS and progression-free survival (PFS). Patients treated with primary RT to the prostate had significantly less progression under abiraterone and a longer abiraterone period than those treated without local prostate RT. Conclusions Local prostate RT significantly improved OS and local control in mCRPC patients treated with abiraterone. The patients treated with primary RT had significantly less progression under abiraterone and a longer abiraterone period than those treated without local prostate RT.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1007/s00066-019-01429-6en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectProstateen_US
dc.subjectSurvivalen_US
dc.subjectLocal recurrenceen_US
dc.subjectHormonotherapyen_US
dc.subjectMetastasisen_US
dc.titleOutcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetateen_US
dc.typearticleen_US
dc.relation.journalSTRAHLENTHERAPIE UND ONKOLOGIEen_US
dc.identifier.volume195en_US
dc.identifier.issue10en_US
dc.identifier.startpage872en_US
dc.identifier.endpage881en_US
dc.identifier.wos000511421900002
dc.contributor.pubmedID30701292


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record